Karlijn van den Bovenkamp

Mrs. Karlijn van den Bovenkamp

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2017 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
KBKarlijn van den Bovenkamp
Karlijn van den Bovenkamp
MNM.G. Noordhuis
M.G. Noordhuis
SOS.F. Oosting
S.F. Oosting
BLBernard F.A.M. van der Laan
Bernard F.A.M. van der Laan
JRJ.L. Roodenburg
J.L. Roodenburg
BPBoudewijn E. C. Plaat
Boudewijn E. C. Plaat

8 January 2018 in Oral Oncology
Verified
Journal Article
Closed access
KBKarlijn van den Bovenkamp
Karlijn van den Bovenkamp
BDBart Dorgelo
Bart Dorgelo
MNMaartje G. Noordhuis
Maartje G. Noordhuis
BLBernard F.A.M. van der Laan
Bernard F.A.M. van der Laan
BVBert van der Vegt
Bert van der Vegt
BPBoudewijn E. C. Plaat
Boudewijn E. C. Plaat

22 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KBKarlijn van den Bovenkamp
Karlijn van den Bovenkamp
Gyorgy B HalmosGyorgy B Halmos
Gyorgy B Halmos
LSLorian Slagter-Menkema
Lorian Slagter-Menkema
BDBoukje van Dijk
Boukje van Dijk
SYShibo YU
Shibo YU
BVBert van der Vegt
Bert van der Vegt
Objectives: This study aimed to evaluate the prognostic significance of DNA methyltransferases (DNMTs) expression, including DNMT1, DNMT3A, and DNMT3B, in assessing the risk of locoregional recurrence after radiotherapy in patients with locally advanced laryngeal squamous cell carcinoma (LSCC), in order to optimize treatment decision making. Methods: A retrospective analysis was performed on pre-treatment biopsy tissues and clinical data from 58 patients with locally advanced LSCC (stages T3–T4, M0) treated with primary curative radiotherapy. DNMT expression was assessed through immunohistochemistry, and Cox regression analysis was applied to examine associations between methylation marker expression, demographic and clinical data, and both locoregional recurrence and disease-specific mortality. Results: Low expression of DNMT3A (p = 0.045) and the presence of locoregional lymph node metastases at diagnosis (N+-status) (p = 0.002) were associated with disease-specific mortality. Clinical N-status was also associated with locoregional recurrent disease after primary radiotherapy (p < 0.001). Expression of DNMT1 and DNMT3B, age, sex, and clinical T-status were not associated with locoregional recurrences or disease-specific mortality. Conclusions: Low expression of DNMT3A and the presence of regional lymph node metastases were independently associated with disease-specific mortality in patients with locally advanced LSCC treated primarily with definitive, curatively intended radiotherapy.